Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 901–1,000 of 1,052
Wu, W., Jia, C., Xu, X., He, Y., Xie, Y., Zhou, Y., Lu, H., Liu, J., Chen, J., & Liu, Y. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s458950 · Cited by 25
Ferri, N., Colombo, E., & Corsini, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111371 · Cited by 27
Ren, Q.-W., Teng, T. K., Ouwerkerk, W., Tse, Y.-K., Tsang, C. T., Wu, M., Tse, H., Voors, A. A., Tromp, J., Lam, C. S. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56790-1 · Cited by 27
Tramontano, D., D'Erasmo, L., Larouche, M., Brisson, D., Lauzière, A., Di Costanzo, A., Bini, S., Minicocci, I., Covino, S., Baratta, F., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119146 · Cited by 23
Atherosclerotic Cardiovascular Disease Risk Prediction Models in China, Japan, and Korea
Nguyen, P. K. P., Zhao, D. H., Okamura, T., Kim, H. C., Wong, N. D., & Yang, E. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.01.006 · Cited by 30
Ivashkin, V. T., Drapkina, O. M., Maevskaya, M. V., Raikhelson, K. L., Okovityi, S. V., Жаркова, М. С., Grechishnikova, V. R., Abdulganieva, D. I., Alekseenko, S. A., Ardatskaya, M. D., et al. (2025) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2025-35-1-94-152 · Cited by 31
Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction
Briones, A. M., Hernanz, R., García‐Redondo, A. B., Rodríguez, C., Blanco‐Colio, L. M., Val‐Blasco, A., Alonso, M. J., & Salaíces, M. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70026 · Cited by 27
Alagaratnam, J., van Bremen, K., Behrens, G. M. N., Boccara, F., Cinque, P. M., Gisslén, M., Guaraldi, G., Konopnicki, D., Kowalska, J. D., Mallon, P. W. G., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00047-5 · Cited by 36
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Kollareth, D. J. M., Deckelbaum, R. J., Liu, Z., Ramakrishnan, R., Jouvene, C. C., Serhan, C. N., Ten, V. S., & Zirpoli, H. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102176 · Cited by 26
The VITamin D and OmegA-3 TriaL (VITAL): Do Results Differ by Sex or Race/Ethnicity?
Bassuk, S. S., Chandler, P. D., Buring, J. E., & Manson, J. E. (2020) · American Journal of Lifestyle Medicine · doi:10.1177/1559827620972035 · Cited by 23
Lipotoxicity dysregulates the immunoproteasome in podocytes and kidneys in type 2 diabetes
Lee, H. S., Suh, J. Y., Kang, B. C., & Lee, E. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00509.2020 · Cited by 24
Albaghdadi, M. S., Ikegami, R., Kassab, M. B., Gardecki, J. A., Kunio, M., Chowdhury, M. M., Khamis, R., Libby, P., Tearney, G. J., & Jaffer, F. A. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315612 · Cited by 25
Lim, S. K., Kim, Y. J., Khang, A. R., & Eckel, R. H. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.09.004 · Cited by 26
Manejo do risco cardiovascular: dislipidemia
Izar, M. C. D. O., Fonseca, F. A. H., Faludi, A. Á., de Araújo, D. B., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-19 · Cited by 34
Ma, T., He, L., Luo, Y., Li, J., Zhang, G., Cheng, X., & Bai, Y. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02889-w · Cited by 23
Miller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 26
Self-citationYu, F., Qi, S., Ji, Y., Wang, X., Fang, S., & Cao, R. (2022) · Medicine · doi:10.1097/md.0000000000029556 · Cited by 23
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029109 · Cited by 23
Self-citationLipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
Szarek, M. J., Bhatt, D. L., Miller, M. J., Brinton, E. A., Jacobson, T. A., Tardif, J., Ballantyne, C. M., Mason, R. P., Ketchum, S. B., Pineda, A. L., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.016 · Cited by 26
Self-citationCastilla‐Guerra, L., Fernández‐Moreno, M. D. C., Jiménez, D. L., & Rico, M. Á. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0563-4 · Cited by 24
Management of Lipid Abnormalities in Patients with Diabetes
Sillars, A., & Sattar, N. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1246-1 · Cited by 24
Pontremoli, R., Bellizzi, V., Bianchi, S., Bigazzi, R., Cernaro, V., Vecchio, L. D., Nicola, L. D., Leoncini, G., Mallamaci, F., Zoccali, C., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00707-2 · Cited by 30
Rossmeisl, M., Pavlišová, J., Bardová, K., Kalendová, V., Buresova, J., Kuda, O., Kroupova, P., Staňková, B., TVRZICKÁ, E., Fišerová, E., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158732 · Cited by 27
Boden, W. E., Baum, S. J., Toth, P. P., Fazio, S., & Bhatt, D. L. (2020) · Future Cardiology · doi:10.2217/fca-2020-0106 · Cited by 25
Self-citationKlooster, C. C. V. ’., Bhatt, D. L., Steg, P. G., Massaro, J. M., Dorresteijn, J. A. N., Westerink, J., Ruigrok, Y. M., de Borst, G. J., Asselbergs, F. W., van der Graaf, Y., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.09.053 · Cited by 26
Self-citationAlsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
Comparing Primary Prevention Recommendations
Stone, N. J., Blumenthal, R. S., Lloyd‐Jones, D. M., & Grundy, S. M. (2020) · Circulation · doi:10.1161/circulationaha.119.044562 · Cited by 23
Kounatidis, D. C., Tentolouris, N., Vallianou, N. G., Mourouzis, I. S., Karampela, Ι., Stratigou, T., Rebelos, E., Kouveletsou, M., Stamatopoulos, V., Tsaroucha, E., et al. (2024) · Metabolites · doi:10.3390/metabo14070388 · Cited by 26
Lipid management in people with peripheral artery disease
Golledge, J., Ward, N. C., & Watts, G. F. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000638 · Cited by 23
High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study
Generoso, G., Benseñor, I. M., Santos, R. D., Staniak, H. L., Sharovsky, R., Santos, I. S., Goulart, A. C., Jones, S. R., Kulkarni, K. R., Blaha, M. J., et al. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.10.006 · Cited by 24
Kim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 22
Platelet reactivity in dyslipidemia: atherothrombotic signaling and therapeutic implications
Yang, M., & Kholmukhamedov, A. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2021.01.256 · Cited by 24
Kapoor, K., Alfaddagh, A., Rifai, M. A., Bhatt, D. L., Budoff, M. J., Nasir, K., Miller, M. J., Welty, F. K., McEvoy, J. W., Dardari, Z., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021431 · Cited by 22
Self-citationHarada, M., Yamakawa, T., Kashiwagi, R., Ohira, A., Sugiyama, M., Sugiura, Y., Kondo, Y., & Terauchi, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255147 · Cited by 24
Camacho‐Muñoz, D., Kiezel‐Tsugunova, M., Kiss, O., Uddin, M., Sundén, M., Ryaboshapkina, M., Lind, L., Oscarsson, J., & Nicolaou, A. (2021) · The FASEB Journal · doi:10.1096/fj.202100380rrr · Cited by 23
Munjral, S., Ahluwalia, P., Jamthikar, A. D., Puvvula, A., Saba, L., Faa, G., Singh, I. M., Chadha, P. S., Turk, M., Johri, A. M., et al. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5026 · Cited by 24
Ohtaki, S., Ashida, K., Matsuo, Y., Moritaka, K., Iwata, S., Nagayama, A., Kawaguchi, A., Koga, H., Yoshinobu, S., Hasuzawa, N., et al. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5671 · Cited by 21
Role of Lipid-Lowering Therapy in Peripheral Artery Disease
Belur, A. D., Shah, A. J., Virani, S. S., Vorla, M., & Kalra, D. K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164872 · Cited by 28
Yang, B., Tseng, P.-T., Hu, X., Zeng, B.-Y., Chang, J. P.-C., Liu, Y., Chu, W.-J., Zhang, S.-S., Zhou, Z.-L., Chu, C.-S., et al. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101196 · Cited by 21
Fat and fatty acids – a scoping review for Nordic Nutrition Recommendations 2023
Retterstøl, K., & Rosqvist, F. (2024) · Food & Nutrition Research · doi:10.29219/fnr.v68.9980 · Cited by 29
Jaffe, I. Z., & Karumanchi, S. A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176347 · Cited by 27
Marine-derived n-3 fatty acids therapy for stroke
Campano, C. G. A., MacLeod, M. J., Thiès, F., Aucott, L. S., & Macleod, M. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012815 · Cited by 22
Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype?
Fredman, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00205 · Cited by 23
van den Hoek, A. M., Pieterman, E. J., van der Hoorn, J. W., Iruarrizaga‐Lejarreta, M., Alonso, C., Verschuren, L., Skjæret, T., Princen, H. M. G., & Fraser, D. A. (2019) · Hepatology Communications · doi:10.1002/hep4.1453 · Cited by 25
Requisite Omega-3 HUFA Biomarker Thresholds for Preventing Murine Lupus Flaring
Wierenga, K. A., Strakovsky, R. S., Benninghoff, A. D., Rajasinghe, L. D., Lock, A. L., Harkema, J. R., & Pestka, J. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01796 · Cited by 22
Penson, P. E., & Banach, M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00887-z · Cited by 26
Sweeney, T. E., Quispe, R., Das, T. M., Juraschek, S. P., Martin, S. S., & Michos, E. D. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1930531 · Cited by 28
Bhatt, R. D., Libby, P., Verma, S., Mason, R. P., & Bhatt, D. L. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.08.003 · Cited by 23
Self-citationUnravelling lipoprotein metabolism with stable isotopes: tracing the flow
Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez‐Martínez, P., Mora, S., Bilianou, H. I., Panotopoulos, G., Katsiki, N., Ooi, T. C., López‐Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190503123911 · Cited by 23
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease Risk
Duell, P. B. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.013 · Cited by 23
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.02.001 · Cited by 22
Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 27
Aggarwal, R., Bhatt, D. L., Steg, P. G., Miller, M. J., Brinton, E. A., Dunbar, R. L., Ketchum, S. B., Tardif, J., Martens, F. M. A. C., Ballantyne, C. M., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038656 · Cited by 23
Self-citationSecondary Prevention after Ischemic Stroke
Furie, K. L., & Kelly, P. J. (2026) · New England Journal of Medicine · doi:10.1056/nejmcp2415601 · Cited by 27
Understanding why REDUCE-IT was positive – Mechanistic overview of eicosapentaenoic acid
Harris, W. S. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.008 · Cited by 22
Genomics of hypertriglyceridemia
Tada, H., Takamura, M., & Kawashiri, M. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.12.005 · Cited by 25
Laing, B. B., Cavadino, A., Ellett, S., & Ferguson, L. R. (2020) · Nutrients · doi:10.3390/nu12041139 · Cited by 26
Central directions for reducing cardiovascular mortality: what can be changed today?
Shlyakhto, E. V., & Баранова, Е. И. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-3983 · Cited by 28
Lipid-lowering therapies in peripheral artery disease: A review
Skeik, N., Nowariak, M. E., Smith, J. E., Alexander, J. Q., Manunga, J. M., Mirza, A. K., & Sullivan, T. M. (2020) · Vascular Medicine · doi:10.1177/1358863x20957091 · Cited by 23
New and Emerging lipid-lowering Therapy
Backes, J. M., & Hilleman, D. E. (2021) · Future Cardiology · doi:10.2217/fca-2020-0217 · Cited by 21
Servadei, F., Anemona, L., Cardellini, M., Scimeca, M., Montanaro, M., Rovella, V., Daniele, F. D., Giacobbi, E., Legramante, I. M., Noce, A., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01277-8 · Cited by 23
Cardiovascular medicine: a year in review
Matteucci, A., BONANNI, M., VERSACI, F., FRATI, G., PERUZZI, M., SANGIORGI, G., Biondi‐Zoccai, G., & MASSARO, G. (2021) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.21.05816-6 · Cited by 23
Resolution-promoting autacoids demonstrate promising cardioprotective effects against heart diseases
Hiram, R. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07230-6 · Cited by 24
Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases
Kotlyarov, S. N., & Котлярова, А. А. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.998291 · Cited by 23
Omega-3 pleiad: The multipoint anti-inflammatory strategy
Batista, E. D. S., Nakandakari, S. C. B. R., da Silva, A. S. R., Pauli, J. R., de Moura, L. P., Ropelle, E. R., Camargo, E. A., & Cintra, D. E. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2146044 · Cited by 25
Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.011 · Cited by 24
Yang, Y., Kim, H., Kim, S., Moon, M. K., & Korean Society of Lipid and Atherosclerosis (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0448 · Cited by 26
Machine Learning Methods in Real-World Studies of Cardiovascular Disease
Zhou, J., You, D., Bai, J., Chen, X., Wu, Y., Wang, Z., Tang, Y., Zhao, Y., & Feng, G. (2023) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2023.0011 · Cited by 29
Halade, G. V., Mat, Y., Gowda, S. G. B., Jain, S., Hui, S., Yadav, H., & Kain, V. (2023) · The FASEB Journal · doi:10.1096/fj.202300184r · Cited by 23
Jayedi, A., Soltani, S., Emadi, A., Ghods, K., & Shab‐Bidar, S. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2251583 · Cited by 26
Caffrey, C., Leamy, A., O’Sullivan, E., Zabetakis, I., Lordan, R., & Nasopoulou, C. (2023) · Marine Drugs · doi:10.3390/md21110549 · Cited by 26
Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
Shang, R., & Rodrigues, B. B. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13199 · Cited by 21
Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review
Formisano, E., Proietti, E., Perrone, G., Demarco, V., Galoppi, P., Stefanutti, C., & Pisciotta, L. (2024) · Nutrients · doi:10.3390/nu16172927 · Cited by 33
Ballantyne, C. M., Manku, M. S., Bays, H. E., Philip, S., Granowitz, C. B., Doyle, R. T., & Juliano, R. A. (2019) · Cardiology and Therapy · doi:10.1007/s40119-019-0131-8 · Cited by 24
Self-citationEligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial
Jia, X., Akeroyd, J. M., Nasir, K., Nambi, V., Ballantyne, C. M., Petersen, L. A., & Virani, S. S. (2019) · Circulation · doi:10.1161/circulationaha.118.038691 · Cited by 21
Self-citationTriglycerides and cardiovascular risk: Apolipoprotein B holds the key
Stock, J. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.004 · Cited by 21
Jin, J., Zhang, H., Cao, Y., Liu, H., Hua, Q., Li, Y., Zhang, Y., Guo, Y., Wu, N., Zhu, C., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01125-1 · Cited by 21
Jia, X., Rifai, M. A., Hussain, A., Martin, S. S., Agarwala, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00895-z · Cited by 27
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01173-3 · Cited by 20
“2 Cholesterol-Lowering Strategy Triglyceride-Lowering Strategy Ezetimibe Evolocuma Alirocumab Icosapent Ethyl Fenofibrate Name IMPROVE-IT FOURIER ODYSSEY REDUCE-IT ACCORD Reference [1] [2] [3] [4] [5] Start date 2005 2012 2012 2011 2001 Size 18,144 patients 27,564 patients 18,924 patients 8,179 patients 5,518 patients…”
MethodDo omega-3 fatty acids benefit health?
Curfman, G. (2020) · JAMA · doi:10.1001/jama.2020.22898 · Cited by 20
Expanding the triglyceride range in clinical trials: therapeutic opportunities
Nordestgaard, A. T., Pradhan, A. D., Everett, B. M., MacFadyen, J. G., Bhatt, D. L., Visseren, F. L. J., Libby, P., Santos, R. D., Nissen, S. E., Nordestgaard, B. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf074 · Cited by 20
Self-citationVromen, T., Brouwers, R. W. M., Jorstad, H. T., Kraaijenhagen, R. A., Spee, R. F., Wittekoek, M. E., Cramer, M. J., van Hal, J. M. C., Hofstra, L., Kuijpers, P. M. J. C., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01585-4 · Cited by 21
Regulatory Compliance of Health Claims on Omega-3 Fatty Acid Food Supplements
Fuentes, J. B., Beara, I. N., & Torović, L. D. (2024) · Foods · doi:10.3390/foods14010067 · Cited by 25
Current pharmacotherapies for atherosclerotic cardiovascular diseases
Park, J., & Oh, G. T. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01116-1 · Cited by 22
The year in cardiology: cardiovascular prevention
Ray, K. K., Laufs, U., Cosentino, F., Lobo, M. D., & Landmesser, U. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz929 · Cited by 20
Lipid-lowering nutraceuticals update on scientific evidence
Derosa, G., Colletti, A., Maffioli, P., D’Angelo, A., Lupi, A., Zito, G., Mureddu, G. F., Raddino, R., Fedele, F., & Cicero, A. F. G. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000970 · Cited by 21
Nitro-fatty acids suppress ischemic ventricular arrhythmias by preserving calcium homeostasis
Mollenhauer, M., Mehrkens, D., Klinke, A., Lange, M., Remane, L., Friedrichs, K. P., Braumann, S., Geißen, S., Simsekyilmaz, S., Nettersheim, F. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71870-6 · Cited by 19
Shirolkar, A. R., Yadav, A., Mandal, T. K., & Dabur, R. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00657-3 · Cited by 20
Demler, O., Liu, Y., Luttmann‐Gibson, H., Watrous, J. D., Lagerborg, K. A., Dashti, H., Giulianini, F., Heath, M., Camargo, C. A., Harris, W. S., et al. (2020) · Metabolites · doi:10.3390/metabo10110431 · Cited by 22
Effect of vitamin D and/or omega‐3 fatty acid supplementation on stroke outcomes: A randomized trial
Rist, P. M., Buring, J. E., Cook, N. R., Manson, J. E., & Rexrode, K. M. (2020) · European Journal of Neurology · doi:10.1111/ene.14623 · Cited by 30
Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus
Román, G., & Stoian, A. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97422 · Cited by 30
Lower triglyceride levels are associated with better endothelial function
Takaeko, Y., Maruhashi, T., Kajikawa, M., Kishimoto, S., Yamaji, T., Harada, T., Hashimoto, Y., Han, Y., Kihara, Y., Chayama, K., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.04.004 · Cited by 19
The role of triglycerides in the origin and progression of atherosclerosis
Padró, T., Muñoz‐García, N., & Badimón, L. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.007 · Cited by 30
Chen, Y., Li, G., Guo, X., Ouyang, N., Li, Z., Ye, N., Yu, S., Yang, H., & Sun, Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153388 · Cited by 22
Summoning STRENGTH to Question the Placebo in REDUCE-IT
Bostrom, J., Beckman, J. A., & Berger, J. S. (2021) · Circulation · doi:10.1161/circulationaha.121.054539 · Cited by 19
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better
Grundy, S. M., Stone, N. J., Blumenthal, R. S., Braun, L. T., Heidenreich, P. A., Lloyd-Jones, D., Orringer, C. E., Saseen, J. J., Smith, S. C., Sperling, L. S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.02.032 · Cited by 20
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 29
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.